Tumor cells overexpress amino acid transporters to meet the increased demand for amino acids. PQ loop repeat-containing (PQLC)2 is a cationic amino acid transporter that might be involved in cancer progression. Here, we show that upregulation of PQLC2 is critical to gastric cancer (GC) development in vitro and in vivo. Both PQLC2 mRNA and protein were overexpressed in GC tissues, especially of the diffuse type.
| INTRODUC TI ON
PQ loop repeat-containing (PQLC)2 is a heptahelical protein with a duplicated PQ loop that functions as an amino acid transporter, mediating the pH-dependent export of the cationic amino acids arginine, histidine, and lysine from lysosomes. 1, 2 PQLC2 is thought to play a role in the lysosomal export of cysteamine-cysteine mixed disulfide, which is formed following cysteamine treatment of patients with cystinosis, a disease characterized by cysteine accumulation in lysosomes. 1 The Saccharomyces cerevisiae homologs Ypq1, Ypq2, and Ypq3 perform an equivalent function in vacuoles and the Schizosaccharomyces pombe homolog Stm1 has been identified as a multicopy suppressor of a ras1 synthetic lethal mutant. 3 Ypq3 regulates cell growth and differentiation by modulating the level of cyclic AMP through the G protein Gpa2. 3, 4 The defect in the Caenorhabditis elegans homolog lysosomal amino acid transporter 1 leads to delayed embryonic development, highlighting the vital function of these transporters. 1 Gastric cancer (GC) is a highly aggressive malignancy that is currently the third most common cause of cancer-related death worldwide, as it is typically diagnosed at an advanced stage. 5, 6 Gastric cancer is the most frequently diagnosed cancer in East Asian countries, 7, 8 especially in Japan and Korea. Up to 45% of patients who undergo curative resection experience local or distant recurrence. 6, 9 In North America and
Europe, approximately 65% of patients have incurable GC or distant metastasis at the time of initial diagnosis. Chemotherapy is effective only in a small subset of GC patients, with advanced cases often showing resistance. [9] [10] [11] To improve the prognosis of high-risk patients, it is important to identify predictive biomarkers and potential therapeutic targets to develop more effective treatment strategies. An ideal candidate target is a protein associated with cell proliferation or survival that is either absent or underexpressed in normal cells but is abundant in cancer cells. As in other solid tumors, agents that block critical interand intracellular signaling pathways have emerged as a treatment strategy for GC. [12] [13] [14] Some agents including trastuzumab and ramucirumab targeting HER-2 15 and vascular endothelial growth factor receptor 2, and CA19-9 17, 18 ; epidermal growth factor receptor overexpression has been correlated with more aggressive tumor behavior and a worse prognosis for patients with GC; 19, 20 hepatocyte growth factor and the hepatocyte growth factor receptor c-MET have also been proposed as potential therapeutic targets. In addition, inhibitors of mTOR, c-MET, insulin-like growth factor receptor, and fibroblast growth factor receptor signaling are currently being investigated in clinical trials. 12, [21] [22] [23] However, most biomarkers identified as therapeutic targets have not yet been sufficiently validated and are still controversial.
We previously reported that the S. pombe PQLC2 homolog Stm1
is associated with the Ras1 gene. 3 Given that human Ras GTPases play an essential role in growth regulation and tumorigenesis and that S. pombe Ras1 regulates MAPK signaling in mating, we speculated that PQLC2 plays a role in GC development. This was investigated in the present study using both in vitro and in vivo approaches. Our results suggest that PQLC2 acts as an oncogene in GC and is a potential therapeutic target for the development of antineoplastic drugs.
| MATERIAL S AND ME THODS

| Materials
Antibodies against Akt, p-Akt (S473), p-c-Raf (S259), p-c-Raf (S338), Erk1/2, and p-Erk1/2 were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibody for GAPDH was purchased from AbFrontier (Seoul, Korea). Anti-FLAG and anti-PQLC2 were purchased from Sigma (St. Louis, MO, USA). 
| Cell culture and reagents
| Tissue samples and microarray construction
Gastric cancer tissue samples were obtained from 180 consecutive patients who underwent elective surgery for GC at the Two GC cores were arrayed per specimen. Four cores of adjacent normal gastric tissue were also sampled for comparison (Table 1) .
Additionally, the ST723 tissue microarray consisting of 21 cases of GC (including 5 diffuse cases, with triplicate cores per case) and 3 adjacent normal tissue samples were purchased from US Biomax (Rockville, MD, USA) and used for analysis.
| Immunohistochemistry analysis
Gastric cancer tissue samples were fixed in 10% buffered formalin and embedded in paraffin. The blocks were cut into 3-μm sections for immunohistochemistry using a rabbit polyclonal anti-PQCL2 Ab and the rabbit EnVision-HRP detection system (Dako, Carpinteria, CA, USA). After deparaffinization, antigen retrieval was carried out in 10 mmol/L sodium citrate buffer (pH 6.0) using a pressure cooker at full power for 4 minutes. The sections were then treated with 3% hydrogen peroxide for 10 minutes before overnight incubation in a humid chamber at 4°C with the primary Ab diluted 1:100 in background-reducing diluent (Dako). A rabbit IgG isotype control without the primary Ab was used as a negative control. The sections were incubated with EnVision reagent for 30 minutes followed by diaminobenzidine for 5 minutes and counterstained with Meyer's hematoxylin. At each step, sections were rinsed several times with TBS with 0.3% Tween-20.
| Reverse transcription-PCR and quantitative real-time PCR
Total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and cDNA was synthesized using TOPscript RT DryMIX (Enzynomics, Seoul, Korea). 
| Generation of cell lines stably expressing PQLC2
To clone the PQLC2 gene, a 0.8-kb DNA fragment amplified by PCR using cDNA from human foreskin fibroblast cells was in- were then expanded in the same selection medium.
| Anchorage independence analysis
Cells were trypsinized and resuspended in DMEM/RPMI supple- 
| Invasion assay
Cell invasion assay was carried out using an insert chamber coated with Matrigel (8-μm pore size; BD Biosciences, San Jose, CA, USA).
Cells (2 × 10 5 ) were plated in the top chamber without serum-free media. The bottom chamber was filled with media supplemented with 20% FBS. After 48 hours, noninvasive cells were removed with a cotton swab. Then the inserts fixed with 4% paraformaldehyde and stained with crystal violet.
| Tumor-forming assay in nude mice
Female Balb/c nude mice (aged 6 weeks) were procured from Orient- Tumor size was measured weekly for 5 weeks and volume (V) was calculated according to the formula V = (length × width 2 )/2.
| Gene knockdown by siRNA and shRNA
The PQLC2 SMART vector lentiviral shRNA constructs had the 
| In vivo antitumor efficacy of PQLC2 silencing in MKN45 cell xenograft model
Animal experiments were carried out according to institutional regulations in a facility that was accredited for laboratory animal 
| RE SULTS
| Overexpression of PQLC2 is associated with clinicopathological parameters in GC
To investigate the association between PQLC2 and GC, PQLC2 expression in GC patients relative to normal tissues was evaluated by immunohistochemistry. PQLC2 was overexpressed in GC; therefore, we examined the relationship between PQLC2 level and clinicopathological parameters such as tumor size, differentiation status, invasion, and tumor grade. Tumors were classified based on staining intensity as follows: 0, no staining; 1, weak; 2, intermediate; and 3, strong. In cases of heterogeneous staining within samples, the higher score was chosen if more than 50% of the cells showed a higher staining intensity. Cases with a score of 0 or 1 were considered as having low PQLC2 expression, and those with a score of 2 or 3 were considered as having high expression ( Figure 1A and Table 1 ). We found that 50.6% (91/180) of patients had low PQLC2 expression whereas 49.5% (89/180) had high expression (Table 1 ). The latter was significantly associated with tumor depth Data were further analyzed to determine the relationship between PQLC2 and patient survival. Kaplan-Meier curves indicated some relevance between high expression of PQLC2 and poor patient survival (P = .043, log-rank test, Figure 1C (Tables 1 and 2 ). Interestingly, PQLC2 was more frequently overexpressed in diffuse-type (4/5, 80.0%) than in intestinal-type (Table S1 ) and high incidence of PQLC2 overexpression in diffuse-type GC was further certified in another set of 9 Korean GC tissue samples. PQLC2 mRNA level was upregulated in 6/9 (66.7%) diffuse-type GC tissue samples relative to adjacent normal tissue ( Figure 2B ,C). These data suggest that PQLC2 contributes to the progression of GC, especially in the diffuse subtype. Although these data indicate that PQLC2 might contribute to the progression of GC, especially in diffusible subtypes, this could not be confirmed due to the limited number of samples.
| Cell proliferation enhanced by PQLC2 in vitro and in vivo
We speculated that the observed overexpression of PQLC2 in GC tissue samples was associated with enhanced tumor cell proliferation. We, therefore, generated HEK293/PQLC2 and/or SNU638/ Consistent with these results, Raf1 activity was increased when PQLC2 was transiently overexpressed using a pCMV-Flag-PQLC2 construct ( Figure 3G ).
| Deficiency of PQLC2 suppresses GC cell proliferation in vitro and in vivo
To confirm the role of PQLC2 in GC, we knocked down PQLC2 using lentiviruses expressing shRNAs (sh1 and sh2; Dharmacon) and 2 siRNAs (si-1 and si-2; ST Pharm.). Of 14 GC cell lines with varying levels of PQLC2 expression ( Figure 4A ,B and 
| D ISCUSS I ON
Cationic amino acid transporter PQLC2 plays a role in the cysteinedepleting mechanism underlying cysteamine therapy of cystinosis;
however, the molecular functions of most PQ-loop family members are unknown, with the exception of cystinosin, a lysosomal cysteine export protein that is defective in cystinosis. 28, 29 In this study, we the correlation between PQLC2 and cancer development. As expected, PQLC2 was highly expressed in GC tissues ( Figure 1 and Table 1 ), particularly in diffuse-type GC (although the sample size was small; Figure 2 and Table 3 ) and in cancer cell lines (Figure 4 ).
The high level of PQLC2 expression was significantly associated with tumor depth (P = .013), lymph node involvement (P = 0.003),
and TNM stage (P = .005). These findings indicated that PQLC2 overexpression is closely related with tumor pathophysiology.
Although PQLC2 had no independent prognostic significance in multivariate analyses (P = .267 compared to P = .043 by univariate analysis), PQLC2 overexpression could have prognostic value. The lack of this significance might be due to a bias in sample composi- 21, 35, 36 In particular, the cross-talk between Akt signaling and amino acid transporter, SLC6A19, and SLC38A1 appears to be an important molecular basis for the development of novel diagnostic markers in cancer patients. Dysregulation of AKT signaling is a hallmark of many cancers. 37, 38 Consistent with these reports, we found that PQLC2 overexpression promoted cell growth, anchorage independence, and tumorigenesis. Raf1/ showed the reduced tumor growth in vivo. Thus, our in vitro and in vivo data indicate that PQLC2 is a critical regulator of GC development.
In conclusion, the results of this study indicate that the amino acid carrier PQLC2 might contribute to dysregulation of the cell cycle and tumor progression. Additional clinical studies and elucidation of molecular mechanisms are warranted to confirm that targeting PQLC2 is an effective therapeutic strategy for preventing the progression of GC. 
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